This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Shire Human Genetic Therapies, Inc., University of Colorado. Active years: 2020.
Company Filing History:
1 out of 86 
1 out of 1,447 
Years Active: 2020
Title: Steven Abman: Innovator in Bronchopulmonary Dysplasia Treatment
Introduction
Steven Abman is a notable inventor based in Aurora, CO (US), recognized for his contributions to medical science, particularly in the treatment of chronic lung disorders. His innovative work has led to the development of a patent that addresses bronchopulmonary dysplasia (BPD), a serious condition affecting premature infants.
Latest Patents
Abman's most recent patent is titled "Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia." This invention provides methods and compositions for treating BPD. The patent outlines a method that includes administering an effective amount of an anti-Flt-1 antibody to individuals suffering from or susceptible to BPD. This treatment aims to reduce the intensity, severity, or frequency of symptoms associated with the condition.
Career Highlights
Throughout his career, Steven Abman has worked with esteemed organizations such as the University of Colorado and Shire Human Genetic Therapies, Inc. His experience in these institutions has significantly contributed to his expertise in the field of medical research and innovation.
Collaborations
Abman has collaborated with notable colleagues, including Gregory Seedorf and Dennis Keefe. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in healthcare.
Conclusion
Steven Abman's work in developing treatments for bronchopulmonary dysplasia showcases his commitment to improving patient outcomes through innovation. His contributions to medical science are invaluable and continue to impact the field positively.